Remove 2029 Remove Insurance Remove Packaging
article thumbnail

STAT+: Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more

STAT

 The priority review voucher bill would almost certainly need to ride with a larger package, such as appropriations legislation, and the unanimous vote by the House Energy and Commerce Committee increases the chances of the voucher program being renewed, at least temporarily, in a government stop-gap funding bill.

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

In April, the US House of Representatives passed the Affordable Insulin Act, which set a price cap of $35 a month for Medicare and private insurance users. For almost all their insulin, these companies manufacture the API and finished dose in-house and package the products themselves instead of using CMOs, GlobalData’s Drugs database shows.

Insurance 131
article thumbnail

How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?

BuzzRx

This law includes a broad package of provisions concerning healthcare, taxes, and climate change. The Inflation Reduction Act will allow the government to negotiate lower prescription drug costs for some of the highest-priced, covered drugs between 2026 and 2029 and beyond.